Appreciate your input.
Yeah sales are the ultimate end result that it needs to be measured on.
The other endorsements i mentioned above are a key part of any medical products’ journey from “development to sales”. So they need to be ticked off for a product/drug to become part of the “standard of care” is my assumption. Then you can expect meaningful adoption and therefore “sales”.
So I was just getting a gauge on your thoughts. Thanks again guys.
Ann: Preliminary Final Report, page-26
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RSH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $32.10M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 197645 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 121551 | 1 |
View Market Depth
| Last trade - 10.06am 18/07/2024 (20 minute delay) ? |
| RSH (ASX) Chart |
Day chart unavailable